Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

740
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
740
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

550
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
550
T Cell Types and Functions01:24

T Cell Types and Functions

643
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
643
Tumor Immunotherapy01:27

Tumor Immunotherapy

411
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
411

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alterations in chromatin organization promote totipotent-like features in a DPPA2/DUX-dependent manner.

The EMBO journal·2026
Same author

ZEB1 drives terminal erythroid maturation by controlling the GATA2-KLF1 regulatory switch.

Nucleic acids research·2026
Same author

CD4<sup>+</sup> T cells impair tumor growth through IL-3 and TNF-dependent vascular damage.

Science (New York, N.Y.)·2026
Same author

Spatial cellular order underlies locally-confined mechanisms of immune resistance in oropharyngeal cancer.

Nature communications·2026
Same author

CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results.

Journal for immunotherapy of cancer·2026
Same author

Activation-dependent lentiviruses enable antigen-specific T cell expansion and transduction.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: May 15, 2025

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.5K

CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses.

Kilyna A Nguyen1, Zhihui Liu2, John S Davies1,3

  • 1Center for Immuno-Oncology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.

Science Advances
|April 9, 2025
PubMed
Summary

Chimeric antigen receptor (CAR)-T cells cause cytokine release syndrome (CRS), unlike T cell receptor (TCR)-T cells. Comparing CD22 CAR-T and TCR-T cells showed CAR-T cells induced inflammation, highlighting TCRs for safer cancer therapies.

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

14.8K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K

Related Experiment Videos

Last Updated: May 15, 2025

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.5K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

14.8K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K

Area of Science:

  • Immunotherapy
  • Oncology
  • Cellular Therapy

Background:

  • Chimeric antigen receptor (CAR) T cells are effective against B cell malignancies.
  • CAR-T therapies can cause inflammatory toxicities like cytokine release syndrome (CRS).
  • T cell receptor (TCR)-engineered T cells rarely cause CRS.

Purpose of the Study:

  • To compare the inflammatory potential of CAR-T and TCR-T cells targeting the same antigen.
  • To investigate how receptor type influences inflammatory responses in a model system.
  • To evaluate the therapeutic efficacy and safety profiles of CD22 CAR-T and CD22 TCR-T cells.

Main Methods:

  • Discovery of a CD22-specific TCR.
  • Comparison of CD22 CAR-T cells and CD22 TCR-T cells in a preclinical model.
  • Assessment of antileukemia activity in xenografts.
  • Analysis of inflammatory pathway upregulation in response to antigen engagement.

Main Results:

  • Both CD22 CAR-T and CD22 TCR-T cells eradicated leukemia in xenografts.
  • Only CD22 CAR-T cells induced dose-dependent systemic inflammation.
  • CAR-T cells showed disproportionate upregulation of inflammatory pathways compared to TCR-T cells.
  • CAR-T cells did not show concordant augmentation of cytotoxicity pathways upon antigen engagement.

Conclusions:

  • Differences in receptor type (CAR vs. TCR) significantly impact inflammatory responses.
  • CAR-T cells elicit greater systemic inflammation than TCR-T cells, even when targeting the same antigen.
  • TCR-engineered T cells may offer a safer alternative for cancer immunotherapy due to reduced inflammatory potential.